|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A Multicenter Study of Viral Aetiology of Community-Acquired Pneumonia in Hospitalized Children in Chinese Mainland显示文摘Community-acquired pneumonia(CAP) is one of the leading causes of morbidity and mortality in children worldwide.In this study,we aimed to describe the aetiology of viral infection of pediatric CAP in Chinese mainland.During November2014 to June 2016,the prospective study was conducted in 13 hospitals.The hospitalized children under 18 years old who met the criteria for CAP were enrolled.The throat swabs or nasopharyngeal aspirates(NPAs) were collected which were then screened 18 respiratory viruses using multiplex PCR assay.Viral pathogens were present in 56.6%(1539/2721) of the enrolled cases,with the detection rate of single virus in 39.8% of the cases and multiple viruses in 16.8% of the cases.The most frequently detected virus was respiratory syncytial virus(RSV)(15.2%,414/2721).The highest detection rate of virus was in <6-month-age group(70.7%,292/413).RSV,human metapneumovirus(HMPV),human parainfluenza viruses(HPIVs) and influenza B virus(Flu B) showed the similar prevalence patterns both in north and south China,but HPIVs,Flu A,human bocavirus(HBoV),human adenovirus(HAdV) and human coronaviruses(HCoVs) showed the distinct circulating patterns in north and south China.Human enterovirus/human rhinovirus(HEV/HRV)(27.6%,27/98),HBoV(18.4%,18/98),RSV(16.3%,16/98) and HMPV(14.3%,14/98) were the most commonly detected viruses in severe pneumonia cases with single virus infection.In conclusion,viral pathogens are frequently detected in pediatric CAP cases and may therefore play a vital role in the aetiology of CAP.RSV was the most important virus in hospitalized children with CAP in Chinese mainland. | Yun Zhu Baoping Xu Changchong Li Zhimin Chen Ling Cao Zhou Fu Yunxiao Shang Aihuan Chen Li Deng Yixiao Bao Yun Sun Limin Ning Shuilian Yu Fang Gu Chunyan Liu Ju Yin Adong Shen Zhengde Xie Kunling Shen | 2021 | Virologica Sinica2021，36，6： | 7 |
| 2 | Methylation of TFPI-2 is an early event of esophageal carcinogenesis显示文摘 | Yan Jia Yunsheng Yang Malcolm V Brock Baoping Cao Qimin Zhan Yazhuo Li Yuanzi Yu James G Herman Mingzhou Guo | 2012 | Epigenomics2012，，2： | 1 |
| 3 | The effect of renin–angiotensin–aldosterone system inhibitors in patients with hypertension and COVID-19:A meta-analysis of randomized controlled trials and propensity score-matched studies显示文摘Background:High-quality evidence for whether the use of renin–angiotensin–aldosterone system(RAAS)in-hibitors worsens clinical outcomes for patients with coronavirus disease 2019(COVID-19)is lacking.The present study aimed to evaluate the effect of RAAS inhibitors on disease severity and mortality in patients with hyper-tension and COVID-19 using randomized controlled trials(RCTs)and propensity score-matched(PSM)studies.Methods:A literature search was conducted with PubMed,Embase,and Scopus databases from 31 December 2019 to 10 January 2022.We included RCTs and PSM studies comparing the risk of severe illness or mortality in patients with hypertension and COVID-19 treated or not treated with RAAS inhibitors.Individual trial data were combined to estimate the pooled odds ratio(OR)with a random-effects model.Results:A total of 17 studies(4 RCTs and 13 PSM studies)were included in the meta-analysis.The use of RAAS inhibitors was not associated with an increased risk of severe illness(OR=1.00,95%confidence interval[CI]:0.88–1.14,I^(2)=28%)or mortality(OR=0.96,95%CI:0.83–1.11,I^(2)=16%)for patients with hypertension and COVID-19.Furthermore,there was no significant difference in the severity of COVID-19 when patients continued or discontinued treatment with RAAS inhibitors(OR=1.01,95%CI:0.78–1.29,I^(2)=0%).Conclusions:This study suggests that there was no association between treatment with RAAS inhibitors and worsened COVID-19 disease outcomes.Our findings support the current guidelines that RAAS inhibitors should be continued in the setting of the COVID-19 pandemic.However,the benefit of RAAS inhibitor medications for COVID-19 patients should be further validated with more RCTs. | Kai Zhang Lanxin Cao Nanxia Xuan Tiancha Huang Baoping Tian Wei Cui Gensheng Zhang Shufang Zhang | 2022 | Journal of Intensive Medicine2022，2，4： | 0 |
| 4 | 《涉过愤怒的海》学术研讨会发言摘要显示文摘2024年1月5日,影片《涉过愤怒的海》学术研讨会在北京电影学院海淀校区召开。研讨会由北京电影学院中国电影文化研究院执行院长、《北京电影学院学报》主编吴冠平教授主持。曹保平导演及各位专家学者分别从创作、学术以及票房市场等多个角度阐发了各自的观点。 | Cao Baoping Rao Shuguang Huangfu Yichuan Chen Xuguang Li Yang Zhang Wei Zhong Dafeng Sun Chengjian Zuo Heng Sai Ren Hu Jianli Li Xingwen | 2024 | 北京电影学院学报2024，，1： | 0 |
| 5 | 《烈日灼心》(英文)显示文摘As the name suggests, Cao Baoping's latest film The Dead End doesn't deliver you to a wholesome, feel-good destination. An intriguing murder mystery, albeit with messy additions, provides more than a few gems and shrieks in an unusually brutal narrative. | Cao Baoping Jiao Huajing CARLOS OTTERY | 2016 | The World of Chinese2016，0，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员